Solid Biosciences (SLDB) Profit After Tax (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.02% |
| Dec 31, 2025 | -8.71% |
| Sep 30, 2025 | -15.95% |
| Jun 30, 2025 | -0.50% |
| Mar 31, 2025 | 7.79% |
| Dec 31, 2024 | -30.18% |
| Sep 30, 2024 | -30.52% |
| Jun 30, 2024 | -3.16% |
| Mar 31, 2024 | -19.60% |
| Dec 31, 2023 | 3.14% |
| Sep 30, 2023 | 14.82% |
| Jun 30, 2023 | 18.09% |
| Mar 31, 2023 | -98.47% |
| Dec 31, 2022 | 25.77% |
| Sep 30, 2022 | 18.66% |
| Jun 30, 2022 | 0.93% |
| Mar 31, 2022 | -36.10% |
| Dec 31, 2021 | -3.49% |
| Sep 30, 2021 | 3.81% |
| Jun 30, 2021 | -10.62% |
| Mar 31, 2021 | 20.89% |
| Dec 31, 2020 | -0.55% |
| Sep 30, 2020 | -11.90% |
| Jun 30, 2020 | 28.87% |
| Mar 31, 2020 | 16.22% |
| Dec 31, 2019 | -8.91% |
| Sep 30, 2019 | -10.29% |
| Jun 30, 2019 | 10.33% |
| Mar 31, 2019 | -34.95% |
| Dec 31, 2018 | -15.25% |
| Sep 30, 2018 | -5.78% |
| Jun 30, 2018 | -13.25% |
| Mar 31, 2018 | -9.59% |
| Dec 31, 2017 | -7.27% |
| Sep 30, 2017 | -19.40% |
| Jun 30, 2017 | 11.74% |